Sarah Cavanaugh
Senior Vice President
Corporate Affairs and Administration
| Investment Date | Original Shares | Original Value | Current Shares | Current Value | % Return | Split Adjustment | Current price |
|---|---|---|---|---|---|---|---|
| Jan 03, 2012 | 1,000.00 | $185.33 | 66.67 | $329.33 | 77.7% | 0.06667 | $4.94 |
Return calculations do not include reinvested cash dividends.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.
© 2019 Celldex Therapeutics, All rights reserved | Site Map | Privacy Policy | Terms of Use | Contact
